Castro, C. F. G.; Nardiello, C.; Hadzic, S.; Kojonazarov, B.; Kraut, S.; Gierhardt, M.; Schaeffer, J.; Bednorz , M.; Quanz, K.; Heger, J.et al.; Korfei, M.; Wilhelm, J.; Hecker, M.; Bartkuhn, M.; Arnhold , S.; Guenther, A.; Seeger, Werner (Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Max Planck Society), W.; Schulz, R.; Weissmann, N.; Sommer, N.; Pak, O.: The Role of the Redox Enzyme p66Shc in Biological Aging of the Lung. AGING AND DISEASE (2024)
Nardiello, C.; Mizikova, I.; Morty, R. E.: Looking ahead: where to next for animal models of bronchopulmonary dysplasia? CELL AND TISSUE RESEARCH 367 (3), pp. 457 - 468 (2017)
Nardiello, C.; Mizikova, I.; Silva, D. M.; Ruiz-Camp, J.; Mayer, K.; Vadasz, I.; Herold, S.; Seeger, W.; Morty, R. E.: Standardisation of oxygen exposure in the development of mouse models for bronchopulmonary dysplasia. DISEASE MODELS & MECHANISMS 10 (2), pp. 185 - 196 (2017)
Nardiello, C.; Ruiz-Camp, J.; Seeger, W.; Morty, R.: A Role For Mir-135b In Normal And Aberrant Post-Natal Lung Development. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 195 (2017)
Rath, P.; Nardiello, C.; Morty, R. E.: A new target for caffeine in the developing lung: endoplasmic reticulum stress? AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 313 (4), pp. L659 - L663 (2017)
Rath, P.; Nardiello, C.; Solaligue, D. E. S.; Agius, R.; Mizikova, I.; Huehn, S.; Mayer, K.; Vadasz, I.; Herold, S.; Runkel, F.et al.; Seeger, W.; Morty, R. E.: Caffeine administration modulates TGF-beta signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. PEDIATRIC RESEARCH 81 (5), pp. 795 - 805 (2017)
Researchers at the Max Planck Institute develop a new pharmacological approach that specifically targets receptor interactions – with implications for immune defense and blood pressure regulation
A team of researchers at the Max Planck Institute for Heart and Lung Research, led by Prof. Dr. Didier Y.R. Stainier, has been awarded a prestigious ERC Proof of Concept (PoC) grant to advance a groundbreaking RNA-based therapeutic strategy for Duchenne Muscular Dystrophy (DMD).